VEGFR
VEGFR(血管内皮生长因子受体)
VEGFR are receptors for vascular endothelial growth factor and belong to receptor tyrosine kinases.
VEGFR 相关产品(193)
- GC33004Cediranib maleate (AZD-2171 maleate)CAS: 857036-77-2纯度: >99.50%
An inhibitor of VEGF receptor tyrosine kinases
- GC33273TAS-115 mesylate (TAS-115 methanesulfonate)CAS: 1688673-09-7纯度: >99.00%
A multi-kinase inhibitor
- GC33840SU1498 (AG 1498)CAS: 168835-82-3纯度: >98.00%
SU1498 (AG 1498)是一种有效的血管内皮生长因子受体2(VEGFR-2)抑制剂,IC 50 值为0.7μM。
- GC34026Tyrosine kinase-IN-1CAS: 705946-27-6纯度: >99.00%
Tyrosinekinase-IN-1是多靶点的酪氨酸激酶抑制剂,抑制KDR,Flt-1,FGFR1和PDGFRα的IC50值分别为4,20,4,2nM。
- GC34216Bevacizumab (Anti-Human VEGF, Humanized Antibody)CAS: 216974-75-3纯度: >98.50%
贝伐单抗Bevacizumab是一种抗VEGF的人源化单克隆抗体,通过与VEGF特异性结合,阻断其与细胞表面相应的受体结合,进而抑制血管生成。
- GC36745Nintedanib esylateCAS: 656247-18-6纯度: >98.00%
Nintedanib esylate,作为一种激酶抑制剂,用于治疗非小细胞肺癌,首过代谢导致口服生物利用度低(~4.7%)。
- GC37664Sorafenib (D3)CAS: 1130115-44-4纯度: >99.00%
An internal standard for the quantification of sorafenib
- GC37665Sorafenib (D4)CAS: 1207560-07-3
Sorafenib D4 (Bay 43-9006 D4) 是 Sorafenib 氘代化合物标准品。Sorafenib 是一种多激酶抑制剂,抑制 Raf-1,B-Raf 和 VEGFR-3 的 IC50 分别为6 nM,20 nM,22 nM。
- GC37772TG 100572 HydrochlorideCAS: 867331-64-4纯度: >99.50%
TG 100572 Hydrochloride 是多靶点激酶抑制剂,抑制受体酪氨酸激酶 (receptor tyrosine kinases) 和Src激酶 (Src kinases); 对VEGFR1,VEGFR2,FGFR1,FGFR2,PDGFRβ,Fgr,Fyn,Hck,Lck,Lyn,Src,Yes 的 IC50 值分别为2,7,2,16,13,5,0.5,6,0.1,0.4,1,0.2 nM。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC33004 | Cediranib maleate (AZD-2171 maleate) | 857036-77-2 | >99.50% | |
An inhibitor of VEGF receptor tyrosine kinases | ||||
| GC33087 | 2,4-Pyrimidinediamine with linker | 1430089-64-7 | - | |
A multi-kinase inhibitor | ||||
| GC33171 | ZD-4190 | 413599-62-9 | >99.00% | |
ZD-4190 is a submicromolar inhibitor of VEGF RTK activity in vitro with IC50 values of 29 ± 4 nM and 708 ± 63 nM for KDR and Flt-1, respectively. | ||||
| GC33173 | TAS-115 | 1190836-34-0 | - | |
A multi-kinase inhibitor | ||||
| GC33271 | R916562 | 1037798-41-6 | - | |
R916562是有效的和有选择性的Axl/VEGF-R2双重抑制剂,IC50值分别为136和24nM。 | ||||
| GC33273 | TAS-115 mesylate (TAS-115 methanesulfonate) | 1688673-09-7 | >99.00% | |
A multi-kinase inhibitor | ||||
| GC33352 | CP-547632 | 252003-65-9 | >98.50% | |
A potent inhibitor of VEGFR2 and bFGF | ||||
| GC33840 | SU1498 (AG 1498) | 168835-82-3 | >98.00% | |
SU1498 (AG 1498)是一种有效的血管内皮生长因子受体2(VEGFR-2)抑制剂,IC 50 值为0.7μM。 | ||||
| GC34026 | Tyrosine kinase-IN-1 | 705946-27-6 | >99.00% | |
Tyrosinekinase-IN-1是多靶点的酪氨酸激酶抑制剂,抑制KDR,Flt-1,FGFR1和PDGFRα的IC50值分别为4,20,4,2nM。 | ||||
| GC34126 | NVP-ACC789 (ACC-789) | 300842-64-2 | >99.50% | |
An inhibitor of VEGFRs | ||||
| GC34159 | Ilorasertib (ABT-348) | 1227939-82-3 | - | |
A multi-kinase inhibitor | ||||
| GC34216 | Bevacizumab (Anti-Human VEGF, Humanized Antibody) | 216974-75-3 | >98.50% | |
贝伐单抗Bevacizumab是一种抗VEGF的人源化单克隆抗体,通过与VEGF特异性结合,阻断其与细胞表面相应的受体结合,进而抑制血管生成。 | ||||
| GC35263 | AG-13958 | 319460-94-1 | >99.50% | |
AG-13958 (AG-013958), a VEGFR tyrosine kinase inhibitor, is in clinical development with ST administration for treatment of choroidal neovascularization associated with age–related macular degeneration (AMD). | ||||
| GC35516 | BIBF 1202 | 894783-71-2 | >99.00% | |
An active metabolite of BIBF 1120 | ||||
| GC36203 | GW806742X | 579515-63-2 | >99.50% | |
GW806742X 是一种混合谱系激酶结构域样蛋白 (MLKL) 抑制剂,结合 MLKL 假激酶域的 Kd 值为 9.3 μM,并具有抗坏死活性。GW806742X 也具有抗 VEGFR2 的活性。 | ||||
| GC36438 | Lenvatinib mesylate | 857890-39-2 | >98.00% / >99.00% | |
An inhibitor of VEGFR2 and VEGFR3 | ||||
| GC36744 | Ningetinib Tosylate | 1394820-77-9 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC36745 | Nintedanib esylate | 656247-18-6 | >98.00% | |
Nintedanib esylate,作为一种激酶抑制剂,用于治疗非小细胞肺癌,首过代谢导致口服生物利用度低(~4.7%)。 | ||||
| GC37047 | Pz-1 | 1800505-64-9 | >99.00% | |
Pz-1是有效地 RET 和 VEGFR2 受体酪氨酸激酶抑制剂,Pz-1抑制这两个野生型激酶的 IC50 值小于 1 nM。 | ||||
| GC37538 | Ripretinib | 1442472-39-0 | >98.00% | |
A KIT and PDGFRα inhibitor | ||||
| GC37664 | Sorafenib (D3) | 1130115-44-4 | >99.00% | |
An internal standard for the quantification of sorafenib | ||||
| GC37665 | Sorafenib (D4) | 1207560-07-3 | - | |
Sorafenib D4 (Bay 43-9006 D4) 是 Sorafenib 氘代化合物标准品。Sorafenib 是一种多激酶抑制剂,抑制 Raf-1,B-Raf 和 VEGFR-3 的 IC50 分别为6 nM,20 nM,22 nM。 | ||||
| GC37771 | TG 100572 | 867334-05-2 | - | |
TG 100572是多靶点激酶抑制剂,抑制受体酪氨酸激酶 (receptor tyrosine kinases) 和Src激酶 (Src kinases); 对VEGFR1,VEGFR2,FGFR1,FGFR2,PDGFRβ,Fgr,Fyn,Hck,Lck,Lyn,Src,Yes 的 IC50 值分别为2,7,2,16,13,5,0.5,6,0.1,0.4,1,0.2 nM。 | ||||
| GC37772 | TG 100572 Hydrochloride | 867331-64-4 | >99.50% | |
TG 100572 Hydrochloride 是多靶点激酶抑制剂,抑制受体酪氨酸激酶 (receptor tyrosine kinases) 和Src激酶 (Src kinases); 对VEGFR1,VEGFR2,FGFR1,FGFR2,PDGFRβ,Fgr,Fyn,Hck,Lck,Lyn,Src,Yes 的 IC50 值分别为2,7,2,16,13,5,0.5,6,0.1,0.4,1,0.2 nM。 | ||||
